glp-1 agonist and pancreatitis A new study showed that use of the GLP1 medications approved for diabetes weight loss including liraglutide (Victoza, Saxenda) & semaglutide (Ozempic, Wegovy, Rybelsus) come with a 9X increased risk New data links GLP-1 agonists

Judith Zarek MSc, PhD is a Knowledge Mobilization Specialist with First Exposure

While lixisenatide and exenatide demonstrate relatively rapid and direct action within central circuits, liraglutide and semaglutide may exert their effects more slowly or indirectly, potentially relying on longer systemic exposure, slow diffusion, or action through peripheralcentral pathways

What the New Research Found About Petrelintides Effectiveness and Side Effects The latest research, a phase 2 trial, involved nearly 500 participants who were overweight or had obesity (the average BMI was 37, the average age was 47, and just over half were female)

Impact of Selected Glucagon-like Peptide-1 Receptor Agonists on Serum Lipids, Adipose Tissue, and Muscle Metabolism-A Narrative Review

There are ongoing studies for these uses, but early data are weak and the risks are unknown

Du, et al., 'The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity', Kidney Int